Origin of robustness in generating drug-resistant malaria parasites

Molecular Biology and Evolution

Volumn 31, Issue 7, 2014, Pages 1649-1660

  Kümpornsin, Krittikorn ^a   Modchang, Charin ^a,b   Heinberg, Adina ^c   Ekland, Eric H ^d   Jirawatcharadech, Piyaporn ^a   Chobson, Pornpimol ^a   Suwanakitti, Nattida ^e   Chaotheing, Sastra ^e   Wilairat, Prapon ^a   Deitsch, Kirk W ^c   Kamchonwongpaisan, Sumalee ^e   Fidock, David A ^d   Kirkman, Laura A ^c   Yuthavong, Yongyuth ^e   Chookajorn, Thanat ^a,b  

^a Mahidol University   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d Department of Microbiology and Immunology Columbia University College of Physicians and Surgeons ^*  (United States)

^e NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY   (Thailand)

Author keywords

drug resistance; evolution; malaria; robustness

Indexed keywords

CHLOROQUINE; CYCLOGUANIL; DIHYDROFOLATE REDUCTASE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; PYRIMETHAMINE; ANTIMALARIAL AGENT;

AMINO ACID SUBSTITUTION; ARTICLE; DRUG RESISTANCE; EPISTASIS; GENE AMPLIFICATION; MOLECULAR EVOLUTION; NONHUMAN; PLASMODIUM FALCIPARUM; DRUG EFFECTS; EVOLUTION; GENE; GENETICS; HUMAN; MALARIA, FALCIPARUM; METABOLISM; PHYSIOLOGY; REPRODUCTIVE FITNESS; SIGNAL TRANSDUCTION;

AMINO ACID SUBSTITUTION; ANTIMALARIALS; BIOLOGICAL EVOLUTION; DRUG RESISTANCE; EPISTASIS, GENETIC; GENES, PROTOZOAN; GENETIC FITNESS; GTP CYCLOHYDROLASE; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PYRIMETHAMINE; SIGNAL TRANSDUCTION; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 84903750991     PISSN: 07374038     EISSN: 15371719     Source Type: Journal    
DOI: 10.1093/molbev/msu140     Document Type: Article

References (49)

1. Anthony MP, Burrows JN, Duparc S, Moehrle JJ, Wells TN. 2012. The global pipeline of new medicines for the control and elimination of malaria. Malar J. 11:316.
2. Bloom JD, Gong LI, Baltimore D. 2010. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328: 1272-1275.
3. Brown KM, Costanzo MS, Xu W, Roy S, Lozovsky ER, Hartl DL. 2010. Compensatory mutations restore fitness during the evolution of dihydrofolate reductase. Mol Biol Evol. 27:2682-2690.
4. Brown KM, Depristo MA, Weinreich DM, Hartl DL. 2009. Temporal constraints on the incorporation of regulatory mutants in evolutionary pathways. Mol Biol Evol. 26:2455-2462.
5. Burg AW, Brown GM. 1968. The biosynthesis of folic acid. 8. Purification and properties of the enzyme that catalyzes the production of formate from carbon atom 8 of guanosine triphosphate. J Biol Chem. 243:2349-2358.
6. Carlton JM. 2007. Toward a malaria haplotype map. Nat Genet. 39:5-6. (Pubitemid 46026491)
7. Carrara VI, Lwin KM, Phyo AP, Ashley E, Wiladphaingern J, Sriprawat K, Rijken M, Boel M, McGready R, Proux S, et al. 2013. Malaria burden and artemisinin resistance in the mobile and migrant population on the Thai-Myanmar border, 1999-2011: An observational study. PLoS Med. 10:e1001398.
8. Chookajorn T, Kumpornsin K. 2011. 'Snakes and Ladders' of drug resistance evolution. Virulence 2:244-247.
9. Chusacultanachai S, Thiensathit P, Tarnchompoo B, Sirawaraporn W, Yuthavong Y. 2002. Novel antifolate resistant mutations of Plasmodium falciparum dihydrofolate reductase selected in Escherichia coli. Mol Biochem Parasitol. 120:61-72. (Pubitemid 34159293)
10. Costanzo MS, Brown KM, Hartl DL. 2011. Fitness trade-offs in the evolution of dihydrofolate reductase and drug resistance in Plasmodium falciparum. PLoS One 6:e19636.
11. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A. 97:6640-6645. (Pubitemid 30412767)
12. Ding XC, Ubben D, Wells TN. 2012. A framework for assessing the risk of resistance for anti-malarials in development. Malar J. 11:292.
13. Ekland EH, Schneider J, Fidock DA. 2011. Identifying apicoplast-Targeting antimalarials using high-Throughput compatible approaches. FASEB J. 25:3583-3593.
14. Epp C, Raskolnikov D, Deitsch KW. 2008. A regulatable transgene expression system for cultured Plasmodium falciparum parasites. Malar J. 7:86.
15. Gong LI, Suchard MA, Bloom JD. 2013. Stability-mediated epistasis constrains the evolution of an influenza protein. Elife 2:e00631.
16. Hartman JLt, Garvik B, Hartwell L. 2001. Principles for the buffering of genetic variation. Science 291:1001-1004.
17. Heinberg A, Siu E, Stern C, Lawrence EA, Ferdig MT, Deitsch KW, Kirkman LA. 2013. Direct evidence for the adaptive role of copy number variation on antifolate susceptibility in Plasmodium falciparum. Mol Microbiol. 88:702-712.
18. Hossain T, Rosenberg I, Selhub J, Kishore G, Beachy R, Schubert K. 2004. Enhancement of folates in plants through metabolic engineering. Proc Natl Acad Sci U S A. 101:5158-5163. (Pubitemid 38469218)
19. Hyde JE. 2008. Antifolate resistance in Africa and the 164-dollar question. Trans R Soc Trop Med Hyg. 102:301-303.
20. Hyde JE. 2005. Exploring the folate pathway in Plasmodium falciparum. Acta Trop. 94:191-206. (Pubitemid 40720326)
21. Japrung D, Leartsakulpanich U, Chusacultanachai S, Yuthavong Y. 2007. Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination. Antimicrob Agents Chemother. 51: 4356-4360. (Pubitemid 350209889)
22. Kidgell C, Volkman SK, Daily J, Borevitz JO, Plouffe D, Zhou Y, Johnson JR, Le Roch K, Sarr O, Ndir O, et al. 2006. A systematic map of genetic variation in Plasmodium falciparum. PLoS Pathog. 2:e57.
23. Kirschner M, Gerhart J. 1998. Evolvability. Proc Natl Acad Sci U S A. 95: 8420-8427. (Pubitemid 28350502)
24. Klaus SM, Kunji ER, Bozzo GG, Noiriel A, de la Garza RD, Basset GJ, Ravanel S, Rebeille F, Gregory JF 3rd, Hanson AD. 2005. Higher plant plastids and cyanobacteria have folate carriers related to those of trypanosomatids. J Biol Chem. 280:38457-38463. (Pubitemid 43853743)
25. Krungkrai J, Yuthavong Y, Webster HK. 1985. Guanosine triphosphate cyclohydrolase in Plasmodium falciparum and other Plasmodium species. Mol Biochem Parasitol. 17:265-276. (Pubitemid 16205653)
26. Lozovsky ER, Chookajorn T, Brown KM, Imwong M, Shaw PJ, Kamchonwongpaisan S, Neafsey DE, Weinreich DM, Hartl DL. 2009. Stepwise acquisition of pyrimethamine resistance in the malaria parasite. Proc Natl Acad Sci U S A. 106:12025-12030.
27. Mackinnon MJ, Marsh K. 2010. The selection landscape of malaria parasites. Science 328:866-871.
28. ManskeM,Miotto O, Campino S, Auburn S, Almagro-Garcia J, Maslen G, O'Brien J, Djimde A, Doumbo O, Zongo I, et al. 2012. Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature 487:375-379.
29. Masel J, Siegal ML. 2009. Robustness: Mechanisms and consequences. Trends Genet. 25:395-403.
30. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD 2012. Global malaria mortality between 1980 and 2010: A systematic analysis. Lancet 379: 413-431.
31. Naidoo I, Roper C. 2013. Mapping 'partially resistant', 'fully resistant', and 'super resistant' malaria. Trends Parasitol. 29:505-515.
32. Nair S, Miller B, Barends M, Jaidee A, Patel J, Mayxay M, Newton P, Nosten F, Ferdig MT, Anderson TJ. 2008. Adaptive copy number evolution in malaria parasites. PLoS Genet. 4:e1000243.
33. Peterson DS, Walliker D, Wellems TE. 1988. Evidence that a point mutation in dihydrofolate reductase-Thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci U S A. 85:9114-9118. (Pubitemid 19001850)
34. Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, Winstanley PA, Estrada-Franco JG, Mollinedo RE, Avila JC, Cespedes JL, et al. 1997. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis. 176:1590-1596. (Pubitemid 27518161)
35. Poelwijk FJ, Kiviet DJ, Weinreich DM, Tans SJ. 2007. Empirical fitness landscapes reveal accessible evolutionary paths. Nature 445:383-386. (Pubitemid 46160901)
36. Queitsch C, Sangster TA, Lindquist S. 2002. Hsp90 as a capacitor of phenotypic variation. Nature 417:618-624. (Pubitemid 34614814)
37. Rathod PK, McErlean T, Lee PC. 1997. Variations in frequencies of drug resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A. 94: 9389-9393. (Pubitemid 27357839)
38. Sawarkar R, Paro R. 2010. Heat shock protein 90: A capacitor or a mutator? J Biosci. 35:163-165.
39. Schulz zur Wiesch P, Engelstadter J, Bonhoeffer S. 2010. Compensation of fitness costs and reversibility of antibiotic resistance mutations. Antimicrob Agents Chemother. 54:2085-2095.
40. Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y, Santi DV. 1997. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc Natl Acad Sci U S A. 94:1124-1129. (Pubitemid 27087815)
41. Smilkstein M, Sriwilaijaroen N, Kelly JX, Wilairat P, Riscoe M. 2004. Simple and inexpensive fluorescence-based technique for highthroughput antimalarial drug screening. Antimicrob Agents Chemother. 48:1803-1806. (Pubitemid 38544392)
42. Specchia V, Piacentini L, Tritto P, Fanti L, D'Alessandro R, Palumbo G, Pimpinelli S, Bozzetti MP. 2010. Hsp90 prevents phenotypic variation by suppressing the mutagenic activity of transposons. Nature 463:662-665.
43. Stephens LL, Shonhai A, Blatch GL. 2011. Co-expression of the Plasmodium falciparum molecular chaperone, PfHsp70, improves the heterologous production of the antimalarial drug target GTP cyclohydrolase I, PfGCHI. Protein Expr Purif. 77:159-165.
44. Toprak E, Veres A, Michel JB, Chait R, Hartl DL, Kishony R. 2011. Evolutionary paths to antibiotic resistance under dynamically sustained drug selection. Nat Genet. 44:101-105.
45. Weinreich DM, Delaney NF, Depristo MA, Hartl DL. 2006. Darwinian evolution can follow only very few mutational paths to fitter proteins. Science 312:111-114.
46. Werner ER, Wachter H, Werner-Felmayer G. 1997. Determination of tetrahydrobiopterin biosynthetic activities by high-performance liquid chromatography with fluorescence detection. Methods Enzymol. 281:53-61.
47. White NJ. 2012. Counter perspective: Artemisinin resistance: Facts, fears, and fables. Am J Trop Med Hyg. 87:785.
48. Woods RJ, Barrick JE, Cooper TF, Shrestha U, Kauth MR, Lenski RE. 2011. Second-order selection for evolvability in a large Escherichia coli population. Science 331:1433-1436.
49. Yuthavong Y, Yuvaniyama J, Chitnumsub P, Vanichtanankul J, Chusacultanachai S, Tarnchompoo B, Vilaivan T, Kamchonwongpaisan S 2005. Malarial (Plasmodium falciparum)) dihydrofolate reductase-Thymidylate synthase: Structural basis for antifolate resistance and development of effective inhibitors. Parasitology 130:249-259..